Gamida Cell Revenue and Competitors

Claim your profile

Jerusalem, USA

Location

$267.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Gamida Cell's estimated annual revenue is currently $19.7M per year.(i)
  • Gamida Cell's estimated revenue per employee is $155,000
  • Gamida Cell's total funding is $267.8M.

Employee Data

  • Gamida Cell has 127 Employees.(i)
  • Gamida Cell grew their employee count by -1% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.8M8922%N/AN/A
#2
$156.1M505-5%$145MN/A
#3
$4.8M62-35%$150MN/A
#4
$30.4M15725%$180.7MN/A
#5
$5.7M37-3%N/AN/A
#6
$256.3M69726%$168.5MN/A
#7
$10.4M6740%N/AN/A
#8
$13.2M85-4%N/AN/A
#9
$29.5M19019%N/AN/A
#10
$3.4M22-58%N/AN/A

Gamida Cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. We are building a broad pipeline based on our proprietary NAM technology platform. Our lead program, NiCord, is in phase 3 development for allogeneic bone marrow transplantation and was granted Breakthrough Therapy Designation by the FDA.

keywords:N/A

$267.8M

Total Funding

127

Number of Employees

$19.7M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Gamida Cell News

2022-04-20 - Gamida Cell Receives FDA Clearance For Lymphoma ...

GDA-201 is “an off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large B cell lymphomas,” Gamida...

2022-04-17 - Gamida Cell Presents Updated One-Year Post-Transplant ...

Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy...

2022-04-17 - UPDATED: Gamida Cell gets IND cleared and clinical hold ...

Paul Schloesser. Associate Editor. The small Boston-based cell therapy outfit Gamida Cell recently axed 10% of its workforce in order to...

2021-10-26 - Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day - Form 6-K

Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day ● Company recently filed an IND application for GDA-201; FDA placed the application on Clinical Hold pending modifications to donor eligibility procedures and ster ...

2019-09-08 - Could Gamida Cell Ltd.'s (NASDAQ:GMDA) Investor Composition Influence The Stock Price?

Every investor in Gamida Cell Ltd. (NASDAQ:GMDA) should be aware of the most powerful shareholder groups. Insiders often own a large ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$40.7M16218%N/A
#2
$7.5M1775%$140.2M
#3
$102M33310%N/A
#4
N/A34039%N/A
#5
$15M35114%$197.5M